InvestmentUpdated on 30 March 2026
Clear.bio (NL) is seeking investment for international expansion
Cofounder & CSO at Clear.bio
Amsterdam, Netherlands
About
Clear.bio is a reimbursed digital intervention for people with Type 2 Diabetes, combining real-time CGM data, personalised nutrition insights, and remote dietitian support to improve glucose regulation and enable lasting behaviour change.
Following successful implementation in Dutch primary care, with growing provider adoption and strong clinical and behavioural outcomes, Clear.bio is transitioning from startup to scale-up. The company is now preparing international expansion, starting with Germany and France.
We are opening conversations with strategic and growth investors who have experience in digital health and scaling healthcare innovations across European markets. Key focus areas include accelerating market access and reimbursement, further strengthening clinical and economic evidence, and scaling commercial operations.
We are particularly interested in partners who bring not only capital, but also strategic support in navigating complex healthcare systems and driving sustainable growth.
Similar opportunities
Project cooperation
Type 2 diabetes DTx pilot in Germany
Madelon Bracke
Cofounder & CSO at Clear.bio
Amsterdam, Netherlands
Partnership
Reimbursed digital diabetes intervention seeking insurer pilots in Europe
Madelon Bracke
Cofounder & CSO at Clear.bio
Amsterdam, Netherlands
Partnership
Companion digital intervention for metabolic therapies (CGM + nutrition + coaching)
Madelon Bracke
Cofounder & CSO at Clear.bio
Amsterdam, Netherlands